Journal article
Role of Human Papillomavirus in Penile Carcinomas Worldwide
European urology, Vol.69(5), pp.953-961
05/2016
DOI: 10.1016/j.eururo.2015.12.007
PMID: 26762611
Abstract
Invasive penile cancer is a rare disease with an approximately 22 000 cases per year. The incidence is higher in less developed countries, where penile cancer can account for up to 10% of cancers among men in some parts of Africa, South America, and Asia.
To describe the human papillomavirus (HPV) DNA prevalence, HPV type distribution, and detection of markers of viral activity (ie, E6*I mRNA and p16INK4a) in a series of invasive penile cancers and penile high-grade squamous intraepithelial lesions (HGSILs) from 25 countries. A total of 85 penile HGSILs and 1010 penile invasive cancers diagnosed from 1983 to 2011 were included.
After histopathologic evaluation of formalin-fixed paraffin-embedded samples, HPV DNA detection and genotyping were performed using the SPF-10/DEIA/LiPA25 system, v.1 (Laboratory Biomedical Products, Rijswijk, The Netherlands). HPV DNA–positive cases were additionally tested for oncogene E6*I mRNA and all cases for p16INK4a expression, a surrogate marker of oncogenic HPV activity.
HPV DNA prevalence and type distributions were estimated.
HPV DNA was detected in 33.1% of penile cancers (95% confidence interval [CI], 30.2–36.1) and in 87.1% of HGSILs (95% CI, 78.0–93.4). The warty-basaloid histologic subtype showed the highest HPV DNA prevalence. Among cancers, statistically significant differences in prevalence were observed only by geographic region and not by period or by age at diagnosis. HPV16 was the most frequent HPV type detected in both HPV-positive cancers (68.7%) and HGSILs (79.6%). HPV6 was the second most common type in invasive cancers (3.7%). The p16INK4a upregulation and mRNA detection in addition to HPV DNA positivity were observed in 69.3% of HGSILs, and at least one of these HPV activity markers was detected in 85.3% of cases. In penile cancers, these figures were 22.0% and 27.1%, respectively.
About a third to a fourth of penile cancers were related to HPV when considering HPV DNA detection alone or adding an HPV activity marker, respectively. The observed HPV type distribution reinforces the potential benefit of current and new HPV vaccines in the reduction of HPV-related penile neoplastic lesions.
About one-third to one-quarter of penile cancers were related to human papillomavirus (HPV). The observed HPV type distribution reinforces the potential benefit of current and new HPV vaccines to prevent HPV-related penile neoplastic lesions.
About one-third to one-quarter of penile cancers were related to human papillomavirus (HPV) when considering HPV DNA detection alone or adding an HPV activity marker. The observed HPV type distribution reinforces the benefit of HPV vaccines in the reduction of HPV-related penile cancer.
Details
- Title: Subtitle
- Role of Human Papillomavirus in Penile Carcinomas Worldwide
- Creators
- Laia Alemany - Institut Català d’Oncologia, Barcelona, SpainAntonio Cubilla - Instituto de Investigaciones en Ciencias de la Salud-Universidad Nacional de Asunción, Asunción, ParaguayGordana Halec - German Cancer Research Center (DKFZ), Heidelberg, GermanyBeatriz Quirós - Institut Català d’Oncologia, Barcelona, SpainEmili Masferrer - Hospital del Mar, Barcelona, SpainSara Tous - Institut Català d’Oncologia, Barcelona, SpainBelén Lloveras - Hospital del Mar, Barcelona, SpainGustavo Hernández-Suarez - Instituto Nacional de Cancerología, Bogotá, ColombiaRay Lonsdale - Norfolk and Norwich University Hospital NHS Foundation Trust, Norfolk, UKLeopoldo Tinoco - Hospital Oncológico, Quito, EcuadorMaria Alejo - Hospital General Hospitalet, Barcelona, SpainIsabel Alvarado-Cabrero - Hospital de Oncología Centro Médico Nacional Siglo XXI, IMSS Mexico, D.F, MexicoJan Laco - The Fingerland Department of Pathology, Charles University in Prague Faculty of Medicine and University Hospital, Hradec Králové, Czech RepublicNuria Guimerà - DDL Diagnostic Laboratory, Rijswijk, The NetherlandsEnrique Poblet - Hospital General Universitario de Albacete, Albacete, SpainLuis E Lombardi - Centro de Investigación Epidemiológica en Salud Sexual y Reproductiva-CIESAR, Hospital General San Juan de Dios, Guatemala City, GuatemalaChristine Bergeron - Laboratoire Cerba, Saint-Ouen-l’Aumône, FranceOmar Clavero - Institut Català d’Oncologia, Barcelona, SpainHai-Rim Shin - National Cancer Center, Goyang-si Gyeonggi-do, South KoreaAnnabelle Ferrera - Universidad Autónoma de Honduras, Tegucigalpa, HondurasAna Felix - Instituto Portugues de Oncologia de Lisboa Francisco Gentil, Lisbon, PortugalJulieta Germar - University of Philippines, Manila, PhilippinesVaclav Mandys - Third Faculty of Medicine, Charles University and Faculty Hospital King's Vineyards, Prague, Czech RepublicChristine Clavel - CHU Reims, Reims, FranceMaria Tzardi - Medical School of University of Crete, Crete, GreeceLuis E Pons - Hospital de Tortosa Verge de la Cinta, Tarragona, SpainVincent Wain - Westmead Hospital, Westmead, AustraliaEugenia Cruz - Centro de Oncología de Coimbra, Coimbra, PortugalCarla Molina - Universidad de Chile, Santiago, ChileJose D Mota - Universidad Central de Venezuela, Caracas, VenezuelaRobert Jach - Jagiellonian University Medical College, Krakow, PolandJulio Velasco - Hospital San Agustín, Asturias, SpainCarla Carrilho - Eduardo Mondlane University and Maputo Central Hospital, Maputo, MozambiqueRuben López-Revilla - Instituto Potosino de Investigación Científica y Tecnológica, San Luis Potosí, MexicoMarc T Goodman - Cancer Research Center, University of Hawaii, Honolulu, HI, USAWim G Quint - DDL Diagnostic Laboratory, Rijswijk, The NetherlandsXavier Castellsagué - Institut Català d’Oncologia, Barcelona, SpainIgnacio Bravo - Institut Català d’Oncologia, Barcelona, SpainMichael Pawlita - German Cancer Research Center (DKFZ), Heidelberg, GermanyNubia Muñoz - National Cancer Institute of Colombia, Bogota, ColombiaF. Xavier Bosch - Institut Català d’Oncologia, Barcelona, SpainSilvia de Sanjosé - Institut Català d’Oncologia, Barcelona, SpainHPV VVAP study group
- Contributors
- Charles F Lynch (Contributor) - University of Iowa, Epidemiology
- Resource Type
- Journal article
- Publication Details
- European urology, Vol.69(5), pp.953-961
- DOI
- 10.1016/j.eururo.2015.12.007
- PMID
- 26762611
- NLM abbreviation
- Eur Urol
- ISSN
- 0302-2838
- eISSN
- 1873-7560
- Publisher
- Elsevier B.V
- Language
- English
- Date published
- 05/2016
- Academic Unit
- Epidemiology
- Record Identifier
- 9984214709002771
Metrics
22 Record Views